RenovoRx, Inc. (RNXT)
NASDAQ: RNXT · Real-Time Price · USD
0.9412
+0.0431 (4.80%)
At close: Jul 30, 2026, 4:00 PM EDT
0.9598
+0.0186 (1.98%)
After-hours: Jul 30, 2026, 6:22 PM EDT
RenovoRx Employees
RenovoRx had 17 employees as of December 31, 2025. The number of employees increased by 7 or 70.00% compared to the previous year.
Employees
17
Change (1Y)
7
Growth (1Y)
70.00%
Revenue / Employee
$87,588
Profits / Employee
-$721,706
Market Cap
42.45M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 17 | 7 | 70.00% |
| Dec 31, 2024 | 10 | 2 | 25.00% |
| Mar 31, 2024 | 10 | 0 | - |
| Dec 31, 2023 | 8 | -1 | -11.11% |
| Sep 30, 2023 | 10 | 0 | - |
| Jun 30, 2023 | 10 | 0 | - |
| Mar 31, 2023 | 10 | 0 | - |
| Dec 31, 2022 | 9 | 3 | 50.00% |
| Sep 30, 2022 | 10 | 0 | - |
| Jun 30, 2022 | 10 | 2 | 25.00% |
| Mar 31, 2022 | 10 | 4 | 66.67% |
| Dec 31, 2021 | 6 | -3 | -33.33% |
| Sep 30, 2021 | 10 | 1 | 11.11% |
| Jun 30, 2021 | 8 | - | - |
| Mar 31, 2021 | 6 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Metagenomi Therapeutics | 118 |
| Seres Therapeutics | 66 |
| eXoZymes | 32 |
| INmune Bio | 21 |
| PDS Biotechnology | 21 |
| Filana Therapeutics | 20 |
| Edesa Biotech | 17 |
| Apollomics | 14 |
RNXT News
- 1 day ago - RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET - GlobeNewsWire
- 5 weeks ago - RenovoRx Transcript: IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 - Transcripts
- 6 weeks ago - RenovoRx Slides: Investor presentation - Filings
- 7 weeks ago - RenovoRx Highlights Peer-Reviewed Publication Supporting Intra-Arterial Gemcitabine Delivery Via TAMP™ in Locally Advanced Pancreatic Cancer - GlobeNewsWire
- 2 months ago - RenovoRx CEO, Shaun Bagai, to Present at the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 on June 23rd - GlobeNewsWire
- 2 months ago - RenovoRx announces FDA Orphan Drug Designation for oxaliplatin - TheFly
- 2 months ago - RenovoRx Announces FDA Orphan Drug Designation Granted: Oxaliplatin for the Treatment of Pancreatic Cancer - GlobeNewsWire
- 2 months ago - RenovoRx announces pharmacokinetic data using TAMP platform - TheFly